

## WHAT IS CLAIMED IS:

1. A method of treating IgE-related disease comprising administering to a patient a therapeutically effective amount of an NNT-1 inhibitor.

2. The method of claim 1 wherein the inhibitor is capable of inhibiting binding to at least one polypeptide selected from the group consisting of:

10 a) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2,4, or 5;

b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1 or 3;

15 c) a biologically active fragment of the polypeptides of a) or b); or

d) a naturally occurring variant of a), b) or c).

3. The method of claim 1 wherein the inhibitor is a selective binding agent.

4. The method of claim 1 wherein the inhibitor is an NNT-1 expression modulator.

25 5. The method of claim 3 wherein the selective binding agent is an antibody or fragment thereof.

6. The method of claim 3 wherein the selective binding agent is a humanized antibody or fragment thereof. The method of claim 3 wherein the selective binding agent is antibody or fragment thereof having a human amino acid sequence.

35 7. The method of claim 3 wherein the selective binding agent is an antibody or fragment thereof having

a human amino acid sequence and human chemical modifications.

8. The method of claim 3 wherein the selective  
5 binding agent is a monoclonal antibody or fragment thereof.

9. The method of claim 3 wherein the selective  
10 binding agent is a polyclonal antibody or fragment thereof.

10. The method of claim 3 wherein the selective  
15 binding agent is a chimeric antibody or fragment thereof.

11. The method of claim 3 wherein the selective  
binding agent is a CDR-grafted antibody or fragment thereof.

12. The method of claim 3 wherein the selective  
20 binding agent is a bispecific, single chain or hetero-antibody or fragment thereof.

13. The method of claim 3 wherein the selective  
25 binding agent further comprises a variable region fragment.

14. The method of claim 3 wherein the selective  
30 binding agent further comprises an Fab, Fab' of F(ab) fragment.

15. The method of claim 3 wherein the selective  
binding agent further comprises an Fc fragment.

35 16. The method of claim 3 wherein the selective binding agent is bound to a detectable label.

17. The method of claim 3 wherein the selective binding agent is produced from a hybridoma.

5 18. A method of modulating IgE levels in a patient comprising administering to said patient a therapeutically effective amount of an NNT-1 selective binding agent.

10 19. The method of claim 18 wherein the selective binding agent is an antagonist antibody.

20. The method of claim 18 wherein the NNT-1 selective binding agent reduces or inhibits the  
15 expression, activity or production of NNT-1.

21. The method of claim 18 wherein the NNT-1 selective binding agent reduces or inhibits the in vivo level of NNT-1.  
20

22. The method of claim 18 wherein the level of IgE is inhibited, decreased or ameliorated.

23. A method for treating allergic disease  
25 comprising administering to a patient a therapeutically effective amount of an NNT-1 inhibitor. .

24. The method of claim 23 wherein the allergic disease is a Type I allergic disease.  
30

25. The method of claim 23 wherein the allergic disease is allergic rhinitis.

26. The method of claim 23 wherein the allergic  
35 disease is eczema.

27. The method of claim 23 wherein the allergic disease is dermatitis.

28. The method of claim 23 wherein the allergic  
5 disease is pollinosis.

29. The method of claim 23 wherein the allergic disease is asthma.

10 30. A method of using an NNT-1 inhibitor to modulate the levels of IgE in a patient.

31. A method of diagnosing an IgE-related disease or susceptibility to an IgE- related disease  
15 comprising:

a) determining the presence or amount of expression of at least one polypeptide selected from the group consisting of:

20 i) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2,4, or 5;

ii) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1 or 3;

iii) a fragment of the polypeptide of i) or ii) above;

25 iv) a naturally occurring variant of a), b) or c); and

b) diagnosing an IgE-related disease or susceptibility to an IgE-related disease based on the presence or amount of expression of the polypeptide.

30

32. A method of preventing an IgE-related disease comprising administering to a patient a therapeutically effective amount of an NNT-1 inhibitor.

35 33. The method of claim 32 wherein the NNT-1 inhibitor is an antagonistic antibody.

34. The method of claim 32 wherein the NNT-1 inhibitor is a soluble receptor protein.

5 35. The method of claim 32 wherein the NNT-1 inhibitor is an expression modulator.

36. A pharmaceutical composition for use in treating IgE-related disease comprising a  
10 therapeutically effective amount of an NNT-1 inhibitor

37. The pharmaceutical composition of claim 36 wherein the NNT-1 inhibitor binds to or inhibits at least one polypeptide selected from the group  
15 consisting of:  
a) a polypeptide comprising the amino acid sequences of .SEQ ID NOS: 2,4,or 5;  
b) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1 or 3;  
20 c) a fragment of the polypeptides of a) or b);  
and  
d) a naturally occurring variant of a), b) or c).